CN112218628A - (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途 - Google Patents

(1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途 Download PDF

Info

Publication number
CN112218628A
CN112218628A CN201980033569.9A CN201980033569A CN112218628A CN 112218628 A CN112218628 A CN 112218628A CN 201980033569 A CN201980033569 A CN 201980033569A CN 112218628 A CN112218628 A CN 112218628A
Authority
CN
China
Prior art keywords
difluoromethylene
amino
carboxylic acid
dystrophy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980033569.9A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN112218628A publication Critical patent/CN112218628A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980033569.9A 2018-03-29 2019-03-29 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途 Pending CN112218628A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650004P 2018-03-29 2018-03-29
US62/650,004 2018-03-29
PCT/US2019/024726 WO2019191525A1 (en) 2018-03-29 2019-03-29 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders

Publications (1)

Publication Number Publication Date
CN112218628A true CN112218628A (zh) 2021-01-12

Family

ID=68056529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980033569.9A Pending CN112218628A (zh) 2018-03-29 2019-03-29 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途

Country Status (10)

Country Link
US (1) US20190298674A1 (https=)
EP (1) EP3758693A4 (https=)
JP (1) JP2021519753A (https=)
KR (1) KR20210009306A (https=)
CN (1) CN112218628A (https=)
AU (1) AU2019243586A1 (https=)
CA (1) CA3095468A1 (https=)
IL (1) IL277599A (https=)
MX (1) MX2020010302A (https=)
WO (1) WO2019191525A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR202021080A2 (tr) * 2020-12-21 2022-07-21 Marmara Ueniversitesi Thi̇el-behnke kornea di̇strofi̇si̇ (tbkd) i̇çi̇n bi̇r yöntem ve söz konusu yöntem i̇le üreti̇len bi̇r yapay doku i̇skelesi̇
EP4482478A4 (en) * 2022-02-27 2026-03-04 Univ Northwestern (3S,4R)-3-AMINO-4-(DIFLUOROMETHYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS USED AS SELECTIVE ORNITHIN AMINOTRANSFERASE ACTIVATORS
KR20250034134A (ko) * 2022-07-06 2025-03-10 오비드 테라퓨틱스 인크. 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용
US20240285565A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
JP2026506097A (ja) * 2023-02-17 2026-02-20 オービッド・セラピューティクス・インコーポレイテッド 多発性硬化症の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペント－１－エン－１－カルボン酸の使用
US20240285563A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106692A9 (en) * 2010-02-25 2012-02-23 Northwestern University Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US20170101364A1 (en) * 2015-10-09 2017-04-13 Richard B. Silverman (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and Related Compounds as GABA Aminotransferase Inactivators for the Treatment of Epilepsy, Addiction and Hepatocellular Carcinoma
CN110461319A (zh) * 2017-02-08 2019-11-15 奥维德医疗公司 治疗癫痫发作紊乱和prader-willi综合征的方法
CN112261938A (zh) * 2018-02-08 2021-01-22 奥维德医疗公司 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗耳鸣、急性感音神经性听力损失、梅尼埃病、图雷特氏综合征、注意缺陷多动障碍和成瘾中的用途
CN112513006A (zh) * 2018-05-25 2021-03-16 西北大学 用于合成(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸的工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
EP2806867A4 (en) * 2012-01-27 2015-09-02 Catalyst Pharmaceutical Partners Inc METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
ES2882126T3 (es) * 2014-11-07 2021-12-01 Univ Northwestern Inhibición de ornitina aminotransferasa con análogos de GABA para el tratamiento de carcinoma hepatocelular
US10632088B2 (en) * 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106692A9 (en) * 2010-02-25 2012-02-23 Northwestern University Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US20130041028A1 (en) * 2010-02-25 2013-02-14 Northwestern University Methods of using (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US20170101364A1 (en) * 2015-10-09 2017-04-13 Richard B. Silverman (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and Related Compounds as GABA Aminotransferase Inactivators for the Treatment of Epilepsy, Addiction and Hepatocellular Carcinoma
WO2017062942A2 (en) * 2015-10-09 2017-04-13 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma
CN110461319A (zh) * 2017-02-08 2019-11-15 奥维德医疗公司 治疗癫痫发作紊乱和prader-willi综合征的方法
CN112261938A (zh) * 2018-02-08 2021-01-22 奥维德医疗公司 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗耳鸣、急性感音神经性听力损失、梅尼埃病、图雷特氏综合征、注意缺陷多动障碍和成瘾中的用途
CN112513006A (zh) * 2018-05-25 2021-03-16 西北大学 用于合成(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸的工艺

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DOUMLELE K，等: "\" A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms\"" *
PAN Y，等: "\"Design, Synthesis, and Biological Activity of a Difluoro-Substituted, Conformationally Rigid Vigabatrin Analogue as a Potent γ-Aminobutyric Acid Aminotransferase Inhibitor\"" *

Also Published As

Publication number Publication date
MX2020010302A (es) 2021-01-08
CA3095468A1 (en) 2019-10-03
JP2021519753A (ja) 2021-08-12
IL277599A (en) 2020-11-30
AU2019243586A1 (en) 2020-10-15
EP3758693A1 (en) 2021-01-06
US20190298674A1 (en) 2019-10-03
EP3758693A4 (en) 2021-06-02
WO2019191525A1 (en) 2019-10-03
KR20210009306A (ko) 2021-01-26

Similar Documents

Publication Publication Date Title
CN112218628A (zh) (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途
JP5878172B2 (ja) 炎症性眼疾患の治療／予防用化合物
JP7664239B2 (ja) エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CN107569494A (zh) 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂
US20250205346A1 (en) Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd
CN110114066B (zh) 含沙丁胺醇的眼科药物
TW200410699A (en) Use of ANECORTAVE acetate for the protection of visual acuity in patients with age related macular degeneration
CN107454841A (zh) 内皮素受体拮抗剂的局部眼用制剂及其用途
TW201406382A (zh) 具視網膜保護功能之複方組成物及應用
Buys et al. Retinitis pigmentosa, nanophthalmos, and optic disc drusen: a case report
KR20250002220A (ko) 안구 약물 전달 삽입물을 투여하여 연령 관련 황반 변성을 예방하는 방법
JP2009519962A (ja) 眼投与用局所メカミルアミン製剤およびその使用
JP2014510115A (ja) 初期の緑内障における正常な視覚機能を回復するｐａｃａｐ（下垂体アデニル酸シクラーゼ活性化ポリペプチド）に基づく眼科用製剤
JP2024516829A (ja) エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
Al-Shahwan et al. Buphthalmos following systemic steroid treatment
Chen et al. Medical Treatment Strategy for Glaucoma
US20260083712A1 (en) Methods for treating patients with ocular comorbidities of an autoimmune disorder
Narayanaswamy et al. Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs
Vienne-Jumeau et al. Spontaneous release of an epiretinal membrane in an adult patient with Stargardt disease–A case report
WO2025128712A1 (en) Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
EP4479061A1 (en) Treatment of anatomical and functional retinal atrophies
BR112022018815B1 (pt) Implante ocular contendo um inibidor de tirosina cinase, seus métodos de preparação, e usos
Isashiki Reticular crack lesion in the ocular fundus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210112